Home LiteratureArticle Details
PMID: 25407511 Published · epublish English Journal Article Research Support, Non-U.S. Gov't Review

Intestinal permeability--a new target for disease prevention and therapy.

BMC gastroenterology ·Vol. 14 ·2014-11-18 ·Pages 189

Bischoff SC, Barbara G, Buurman W, Ockhuizen T, Schulzke JD, Serino M, Tilg H, Watson A, Wells JM

Abstract

Data are accumulating that emphasize the important role of the intestinal barrier and intestinal permeability for health and disease. However, these terms are poorly defined, their assessment is a matter of debate, and their clinical significance is not clearly established. In the present review, current knowledge on mucosal barrier and its role in disease prevention and therapy is summarized. First, the relevant terms 'intestinal barrier' and 'intestinal permeability' are defined. Secondly, the key element of the intestinal barrier affecting permeability are described. This barrier represents a huge mucosal surface, where billions of bacteria face the largest immune system of our body. On the one hand, an intact intestinal barrier protects the human organism against invasion of microorganisms and toxins, on the other hand, this barrier must be open to absorb essential fluids and nutrients. Such opposing goals are achieved by a complex anatomical and functional structure the intestinal barrier consists of, the functional status of which is described by 'intestinal permeability'. Third, the regulation of intestinal permeability by diet and bacteria is depicted. In particular, potential barrier disruptors such as hypoperfusion of the gut, infections and toxins, but also selected over-dosed nutrients, drugs, and other lifestyle factors have to be considered. In the fourth part, the means to assess intestinal permeability are presented and critically discussed. The means vary enormously and probably assess different functional components of the barrier. The barrier assessments are further hindered by the natural variability of this functional entity depending on species and genes as well as on diet and other environmental factors. In the final part, we discuss selected diseases associated with increased intestinal permeability such as critically illness, inflammatory bowel diseases, celiac disease, food allergy, irritable bowel syndrome, and--more recently recognized--obesity and metabolic diseases. All these diseases are characterized by inflammation that might be triggered by the translocation of luminal components into the host. In summary, intestinal permeability, which is a feature of intestinal barrier function, is increasingly recognized as being of relevance for health and disease, and therefore, this topic warrants more attention.

MeSH Terms
Animals Biomarkers/metabolism Critical Illness Diet Fatty Liver/metabolism Histamine/metabolism Humans Inflammatory Bowel Diseases/metabolism Intestinal Mucosa/immunology,metabolism Intestines/immunology,microbiology Ion Transport Obesity/metabolism Peptide Hydrolases/metabolism Permeability Prebiotics Probiotics/administration & dosage Receptor, Cannabinoid, CB1/metabolism Serotonin/metabolism
Chemicals
Biomarkers Prebiotics Receptor, Cannabinoid, CB1 Serotonin Histamine Peptide Hydrolases
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Bischoff Stephan C
Barbara Giovanni
Buurman Wim
Ockhuizen Theo
Schulzke Jörg-Dieter
Serino Matteo
Tilg Herbert
Watson Alastair
Wells Jerry M
References (265)
265 references, click to expand
  1. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43.
    Nature. 2009 Oct 29;461(7268):1282-6 PMID: 19865172
  2. Level of activation of the unfolded protein response correlates with Paneth cell apoptosis in human small intestine exposed to ischemia/reperfusion.
    Gastroenterology. 2011 Feb;140(2):529-539.e3 PMID: 20965186
  3. A moderate weight reduction through dietary intervention decreases hepatic fat content in patients with non-alcoholic fatty liver disease (NAFLD): a pilot study.
    Eur J Nutr. 2013 Mar;52(2):527-35 PMID: 22543623
  4. Effects of quercetin studied in colonic HT-29/B6 cells and rat intestine in vitro.
    Ann N Y Acad Sci. 2012 Jul;1258:100-7 PMID: 22731722
  5. Gut microbiota composition is associated with body weight, weight gain and biochemical parameters in pregnant women.
    Br J Nutr. 2010 Jul;104(1):83-92 PMID: 20205964
  6. Whole grain, bran, and germ intake and risk of type 2 diabetes: a prospective cohort study and systematic review.
    PLoS Med. 2007 Aug;4(8):e261 PMID: 17760498
  7. The microbiome and rheumatoid arthritis.
    Nat Rev Rheumatol. 2011 Oct;7(10):569-78 PMID: 21862983
  8. Commensal Akkermansia muciniphila exacerbates gut inflammation in Salmonella Typhimurium-infected gnotobiotic mice.
    PLoS One. 2013;8(9):e74963 PMID: 24040367
  9. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome.
    Aliment Pharmacol Ther. 2008 Oct 15;28(8):994-1002 PMID: 18671775
  10. Targeting gut microbiota in obesity: effects of prebiotics and probiotics.
    Nat Rev Endocrinol. 2011 Nov;7(11):639-46 PMID: 21826100
  11. Increased permeability in dextran sulphate colitis in rats: time course of development and effect of butyrate.
    Scand J Gastroenterol. 2000 Oct;35(10):1053-9 PMID: 11099058
  12. A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria.
    Science. 2000 Jun 23;288(5474):2222-6 PMID: 10864873
  13. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial.
    Gastroenterology. 2003 May;124(5):1202-9 PMID: 12730861
  14. The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome.
    Gastroenterology. 2011 Aug;141(2):507-16 PMID: 21684281
  15. Ischaemia-induced mucus barrier loss and bacterial penetration are rapidly counteracted by increased goblet cell secretory activity in human and rat colon.
    Gut. 2013 Feb;62(2):250-8 PMID: 22637697
  16. Regulation of tight junction permeability by intestinal bacteria and dietary components.
    J Nutr. 2011 May;141(5):769-76 PMID: 21430248
  17. Sucrose: a novel permeability marker for gastroduodenal disease.
    Gastroenterology. 1993 Jun;104(6):1619-26 PMID: 8500718
  18. EspM2 is a RhoA guanine nucleotide exchange factor.
    Cell Microbiol. 2010 May 1;12(5):654-64 PMID: 20039879
  19. AMPylation of Rho GTPases by Vibrio VopS disrupts effector binding and downstream signaling.
    Science. 2009 Jan 9;323(5911):269-72 PMID: 19039103
  20. Modulation of the gut microbiota by nutrients with prebiotic properties: consequences for host health in the context of obesity and metabolic syndrome.
    Microb Cell Fact. 2011 Aug 30;10 Suppl 1:S10 PMID: 21995448
  21. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity.
    PLoS One. 2007;2(12):e1308 PMID: 18074031
  22. Dietary fructose and intestinal barrier: potential risk factor in the pathogenesis of nonalcoholic fatty liver disease.
    J Nutr Biochem. 2009 Sep;20(9):657-62 PMID: 19679262
  23. Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation--a randomized, double-blind trial.
    Am J Transplant. 2005 Jan;5(1):125-30 PMID: 15636620
  24. Probiotic bacteria regulate intestinal epithelial permeability in experimental ileitis by a TNF-dependent mechanism.
    PLoS One. 2012;7(7):e42067 PMID: 22848704
  25. Gut mucosal cell damage in meningococcal sepsis in children: relation with clinical outcome.
    Crit Care Med. 2010 Jan;38(1):133-7 PMID: 19730255
  26. The gut microbiota as an environmental factor that regulates fat storage.
    Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15718-23 PMID: 15505215
  27. Liver fatty acid-binding protein: an early and sensitive plasma marker of hepatocellular damage and a reliable predictor of graft viability after liver transplantation from non-heart-beating donors.
    Transplant Proc. 2005 Jan-Feb;37(1):413-6 PMID: 15808662
  28. Bacteroides fragilis enterotoxin cleaves the zonula adherens protein, E-cadherin.
    Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14979-84 PMID: 9844001
  29. Intestinal-FABP and liver-FABP: Novel markers for severe abdominal injury.
    Acad Emerg Med. 2010 Jul;17(7):729-35 PMID: 20653587
  30. A metagenome-wide association study of gut microbiota in type 2 diabetes.
    Nature. 2012 Oct 4;490(7418):55-60 PMID: 23023125
  31. Dysbiosis of Gut Microbiota (DOGMA)--a novel theory for the development of Polycystic Ovarian Syndrome.
    Med Hypotheses. 2012 Jul;79(1):104-12 PMID: 22543078
  32. Commensal enteric bacteria engender a self-limiting humoral mucosal immune response while permanently colonizing the gut.
    Infect Immun. 1995 Oct;63(10):3904-13 PMID: 7558298
  33. Increased gut permeability and microbiota change associate with mesenteric fat inflammation and metabolic dysfunction in diet-induced obese mice.
    PLoS One. 2012;7(3):e34233 PMID: 22457829
  34. Innate immune dysfunction in inflammatory bowel disease.
    J Intern Med. 2012 May;271(5):421-8 PMID: 22324936
  35. Bacterial population and innate immunity-related genes in rat gastrointestinal tract are altered by vitamin A-deficient diet.
    J Nutr Biochem. 2009 Jan;20(1):70-7 PMID: 18495461
  36. Intestinal inflammation targets cancer-inducing activity of the microbiota.
    Science. 2012 Oct 5;338(6103):120-3 PMID: 22903521
  37. Interactions among secretory immunoglobulin A, CD71, and transglutaminase-2 affect permeability of intestinal epithelial cells to gliadin peptides.
    Gastroenterology. 2012 Sep;143(3):698-707.e1-4 PMID: 22750506
  38. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.
    Gastroenterology. 2000 Aug;119(2):305-9 PMID: 10930365
  39. Probiotic bacteria enhance murine and human intestinal epithelial barrier function.
    Gastroenterology. 2001 Sep;121(3):580-91 PMID: 11522742
  40. The epithelial barrier is maintained by in vivo tight junction expansion during pathologic intestinal epithelial shedding.
    Gastroenterology. 2011 Apr;140(4):1208-1218.e1-2 PMID: 21237166
  41. Enterotypes of the human gut microbiome.
    Nature. 2011 May 12;473(7346):174-80 PMID: 21508958
  42. The effect of a bifidobacter supplemented bovine milk on intestinal permeability of preterm infants.
    Early Hum Dev. 2007 Sep;83(9):575-9 PMID: 17229535
  43. Monitoring myeloablative therapy-induced small bowel toxicity by serum citrulline concentration: a comparison with sugar permeability tests.
    Cancer. 2005 Jan 1;103(1):191-9 PMID: 15573372
  44. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection.
    Gastroenterology. 2012 Mar;142(3):490-6 PMID: 22155369
  45. Intestinal permeability in coeliac disease: insight into mechanisms and relevance to pathogenesis.
    Gut. 2012 Sep;61(9):1355-64 PMID: 21890812
  46. Increased intestinal sugar permeability after challenge in children with cow's milk allergy or intolerance.
    Allergy. 1994 Mar;49(3):142-6 PMID: 8198245
  47. A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain.
    Pediatrics. 2010 Dec;126(6):e1445-52 PMID: 21078735
  48. Subversion of actin dynamics by EspM effectors of attaching and effacing bacterial pathogens.
    Cell Microbiol. 2008 Jul;10(7):1429-41 PMID: 18331467
  49. Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases.
    Int J Colorectal Dis. 2008 Oct;23(10):985-92 PMID: 18629518
  50. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome.
    Gastroenterology. 2009 Oct;137(4):1425-34 PMID: 19596012
  51. Early increase in intestinal permeability in patients with severe acute pancreatitis: correlation with endotoxemia, organ failure, and mortality.
    J Gastrointest Surg. 1999 May-Jun;3(3):252-62 PMID: 10481118
  52. Mechanism of protection of transepithelial barrier function by Lactobacillus salivarius: strain dependence and attenuation by bacteriocin production.
    Am J Physiol Gastrointest Liver Physiol. 2012 Nov 1;303(9):G1029-41 PMID: 22961803
  53. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.
    Gastroenterology. 2012 Apr;142(4):711-725.e6 PMID: 22326434
  54. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease.
    Lancet. 2000 Apr 29;355(9214):1518-9 PMID: 10801176
  55. Effect on human cells of environmental Vibrio parahaemolyticus strains carrying type III secretion system 2.
    Infect Immun. 2010 Jul;78(7):3280-7 PMID: 20479084
  56. Lactobacillus casei DN-114 001 inhibits the increase in paracellular permeability of enteropathogenic Escherichia coli-infected T84 cells.
    Res Microbiol. 2005 Mar;156(2):256-62 PMID: 15748992
  57. Proteomic analyses of the two mucus layers of the colon barrier reveal that their main component, the Muc2 mucin, is strongly bound to the Fcgbp protein.
    J Proteome Res. 2009 Jul;8(7):3549-57 PMID: 19432394
  58. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators.
    Gut. 2009 Feb;58(2):196-201 PMID: 18824556
  59. Review article: probiotics for the treatment of irritable bowel syndrome--focus on lactic acid bacteria.
    Aliment Pharmacol Ther. 2012 Feb;35(4):403-13 PMID: 22225517
  60. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease.
    Gut. 2007 Jan;56(1):61-72 PMID: 16822808
  61. Enhancement of intestinal inflammation in mice lacking interleukin 10 by deletion of the serotonin reuptake transporter.
    Neurogastroenterol Motil. 2010 Jul;22(7):826-34, e229 PMID: 20219086
  62. Physiological and pathophysiological functions of intestinal mast cells.
    Semin Immunopathol. 2009 Jul;31(2):185-205 PMID: 19533134
  63. Exercise-induced splanchnic hypoperfusion results in gut dysfunction in healthy men.
    PLoS One. 2011;6(7):e22366 PMID: 21811592
  64. Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission.
    Scand J Gastroenterol. 2008;43(7):842-8 PMID: 18584523
  65. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability.
    Gut. 2009 Aug;58(8):1091-103 PMID: 19240062
  66. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.
    Gut. 2004 Nov;53(11):1617-23 PMID: 15479682
  67. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier.
    Am J Physiol Gastrointest Liver Physiol. 2008 Jan;294(1):G208-16 PMID: 17962355
  68. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome.
    Am J Gastroenterol. 2011 Jul;106(7):1290-8 PMID: 21427712
  69. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection.
    Am J Gastroenterol. 2012 Jul;107(7):1079-87 PMID: 22450732
  70. Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens.
    Nature. 2013 Oct 3;502(7469):96-9 PMID: 23995682
  71. An obesity-associated gut microbiome with increased capacity for energy harvest.
    Nature. 2006 Dec 21;444(7122):1027-31 PMID: 17183312
  72. Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis.
    Liver Int. 2008 Aug;28(7):1026-33 PMID: 18397235
  73. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis.
    Gut. 2014 Aug;63(8):1275-83 PMID: 24021287
  74. Barrier dysfunction due to distinct defensin deficiencies in small intestinal and colonic Crohn's disease.
    Mucosal Immunol. 2008 Nov;1 Suppl 1:S67-74 PMID: 19079235
  75. Lactobacillus casei Shirota protects from fructose-induced liver steatosis: a mouse model.
    J Nutr Biochem. 2013 Mar;24(3):531-8 PMID: 22749137
  76. Influence of a high-fat diet on gut microbiota, intestinal permeability and metabolic endotoxaemia.
    Br J Nutr. 2012 Sep;108(5):801-9 PMID: 22717075
  77. Impact of the administration of probiotics on mortality in critically ill adult patients: a meta-analysis of randomized controlled trials.
    Chest. 2013 Mar;143(3):646-55 PMID: 23460153
  78. Early diagnosis of intestinal ischemia using urinary and plasma fatty acid binding proteins.
    Ann Surg. 2011 Feb;253(2):303-8 PMID: 21245670
  79. Evaluation of a triple sugar test of colonic permeability in humans.
    Acta Physiol Scand. 2004 Oct;182(2):171-7 PMID: 15450113
  80. Intestinal barrier function in health and gastrointestinal disease.
    Neurogastroenterol Motil. 2012 Jun;24(6):503-12 PMID: 22583600
  81. Type 2 diabetes as an inflammatory disease.
    Nat Rev Immunol. 2011 Feb;11(2):98-107 PMID: 21233852
  82. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans.
    Am J Clin Nutr. 2011 Jul;94(1):58-65 PMID: 21543530
  83. Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis.
    Gut. 2014 Feb;63(2):281-91 PMID: 23426893
  84. Probiotics and commensals reverse TNF-alpha- and IFN-gamma-induced dysfunction in human intestinal epithelial cells.
    Gastroenterology. 2006 Mar;130(3):731-46 PMID: 16530515
  85. 'Gut health': a new objective in medicine?
    BMC Med. 2011;9:24 PMID: 21401922
  86. Abdominal obesity and metabolic syndrome.
    Nature. 2006 Dec 14;444(7121):881-7 PMID: 17167477
  87. Faecalibacterium prausnitzii and human intestinal health.
    Curr Opin Microbiol. 2013 Jun;16(3):255-61 PMID: 23831042
  88. The gut as communicator between environment and host: immunological consequences.
    Eur J Pharmacol. 2011 Sep;668 Suppl 1:S16-32 PMID: 21816150
  89. Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women.
    Gut. 2013 Aug;62(8):1112-21 PMID: 23135760
  90. Effects of glutamine supplements and radiochemotherapy on systemic immune and gut barrier function in patients with advanced esophageal cancer.
    Ann Surg. 1998 Apr;227(4):485-91 PMID: 9563534
  91. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake.
    J Nutr. 2008 Aug;138(8):1452-5 PMID: 18641190
  92. Interactions between the microbiota and the immune system.
    Science. 2012 Jun 8;336(6086):1268-73 PMID: 22674334
  93. Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment.
    PLoS One. 2011;6(11):e27961 PMID: 22132181
  94. Metabolic adaptation to a high-fat diet is associated with a change in the gut microbiota.
    Gut. 2012 Apr;61(4):543-53 PMID: 22110050
  95. Examining the role of Paneth cells in the small intestine by lineage ablation in transgenic mice.
    J Biol Chem. 1997 Sep 19;272(38):23729-40 PMID: 9295317
  96. Intestinal MicrobiOMICS to define health and disease in human and mice.
    Curr Pharm Biotechnol. 2012 Apr;13(5):746-58 PMID: 22122483
  97. Analysis of epithelial cell shedding and gaps in the intestinal epithelium.
    Methods Mol Biol. 2011;763:105-14 PMID: 21874447
  98. Tight junction-associated MARVEL proteins marveld3, tricellulin, and occludin have distinct but overlapping functions.
    Mol Biol Cell. 2010 Apr 1;21(7):1200-13 PMID: 20164257
  99. Disruption of the epithelial apical-junctional complex by Helicobacter pylori CagA.
    Science. 2003 May 30;300(5624):1430-4 PMID: 12775840
  100. Protein kinase C signaling regulates ZO-1 translocation and increased paracellular flux of T84 colonocytes exposed to Clostridium difficile toxin A.
    J Biol Chem. 2002 Feb 8;277(6):4247-54 PMID: 11729192
  101. Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation.
    Gut. 2003 Mar;52(3):439-51 PMID: 12584232
  102. Health claim regulation of probiotics in the USA and the EU: is there a middle way?
    Benef Microbes. 2013 Mar 1;4(1):109-15 PMID: 23257017
  103. Paneth cell defensins and the regulation of the microbiome: détente at mucosal surfaces.
    Gut Microbes. 2010 Nov-Dec;1(6):401-6 PMID: 21468224
  104. Polyphenol supplementation as a complementary medicinal approach to treating inflammatory bowel disease.
    Curr Med Chem. 2011;18(31):4851-65 PMID: 21919842
  105. Microbial butyrate and its role for barrier function in the gastrointestinal tract.
    Ann N Y Acad Sci. 2012 Jul;1258:52-9 PMID: 22731715
  106. Serotonin reuptake transporter (SERT) plays a critical role in the onset of fructose-induced hepatic steatosis in mice.
    Am J Physiol Gastrointest Liver Physiol. 2010 Mar;298(3):G335-44 PMID: 19713474
  107. Multifunctional strands in tight junctions.
    Nat Rev Mol Cell Biol. 2001 Apr;2(4):285-93 PMID: 11283726
  108. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review.
    Am J Gastroenterol. 2009 Apr;104(4):1033-49; quiz 1050 PMID: 19277023
  109. Review article: the treatment of functional abdominal bloating and distension.
    Aliment Pharmacol Ther. 2011 May;33(10):1071-86 PMID: 21488913
  110. Intestinal goblet cells and mucins in health and disease: recent insights and progress.
    Curr Gastroenterol Rep. 2010 Oct;12(5):319-30 PMID: 20703838
  111. Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier.
    Am J Physiol Gastrointest Liver Physiol. 2010 Jun;298(6):G851-9 PMID: 20224007
  112. Intestinal microflora and metabolic diseases.
    Diabetes Metab. 2009 Sep;35(4):262-72 PMID: 19419895
  113. The gut barrier: new acquisitions and therapeutic approaches.
    J Clin Gastroenterol. 2012 Oct;46 Suppl:S12-7 PMID: 22955350
  114. Lactobacillus plantarum MB452 enhances the function of the intestinal barrier by increasing the expression levels of genes involved in tight junction formation.
    BMC Microbiol. 2010;10:316 PMID: 21143932
  115. Mucin dynamics and enteric pathogens.
    Nat Rev Microbiol. 2011 Apr;9(4):265-78 PMID: 21407243
  116. Role of the gut in multiple organ failure: bacterial translocation and permeability changes.
    World J Surg. 1996 May;20(4):411-7 PMID: 8662128
  117. Citrulline as a marker for chemotherapy induced mucosal barrier injury in pediatric patients.
    Pediatr Blood Cancer. 2009 Dec 15;53(7):1188-94 PMID: 19688831
  118. Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life.
    JPEN J Parenter Enteral Nutr. 2011 May;35(3):308-16 PMID: 21527593
  119. The conventional short-circuiting technique under-short-circuits most epithelia.
    J Membr Biol. 1981 Apr 30;59(3):173-7 PMID: 7241580
  120. The interaction of large bowel microflora with the colonic mucus barrier.
    Int J Inflam. 2010 Oct 03;2010:321426 PMID: 21152122
  121. Moving pictures of the human microbiome.
    Genome Biol. 2011;12(5):R50 PMID: 21624126
  122. Involvement of tissue bacteria in the onset of diabetes in humans: evidence for a concept.
    Diabetologia. 2011 Dec;54(12):3055-61 PMID: 21976140
  123. IgA responses in the intestinal mucosa against pathogenic and non-pathogenic microorganisms.
    Microbes Infect. 2001 Oct;3(12):1021-35 PMID: 11580989
  124. Intestinal barrier function: molecular regulation and disease pathogenesis.
    J Allergy Clin Immunol. 2009 Jul;124(1):3-20; quiz 21-2 PMID: 19560575
  125. MUCUS IN INTESTINAL CONTENTS OF GERMFREE RATS.
    J Exp Med. 1965 Feb 1;121:201-13 PMID: 14264267
  126. Altered permeability in inflammatory bowel disease: pathophysiology and clinical implications.
    Curr Opin Gastroenterol. 2007 Jul;23(4):379-83 PMID: 17545772
  127. The role of the gut microbiota in energy metabolism and metabolic disease.
    Curr Pharm Des. 2009;15(13):1546-58 PMID: 19442172
  128. Barrier effects of nutritional factors.
    Ann N Y Acad Sci. 2009 May;1165:267-73 PMID: 19538315
  129. A high-fat diet is associated with endotoxemia that originates from the gut.
    Gastroenterology. 2012 May;142(5):1100-1101.e2 PMID: 22326433
  130. Evolution of mammals and their gut microbes.
    Science. 2008 Jun 20;320(5883):1647-51 PMID: 18497261
  131. Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein Claudin-1 transcription.
    Dig Dis Sci. 2012 Dec;57(12):3126-35 PMID: 22684624
  132. Helicobacter pylori CagA induces a transition from polarized to invasive phenotypes in MDCK cells.
    Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16339-44 PMID: 16258069
  133. Escherichia coli alpha-haemolysin induces focal leaks in colonic epithelium: a novel mechanism of bacterial translocation.
    Cell Microbiol. 2007 Oct;9(10):2530-40 PMID: 17587334
  134. Diets with high or low protein content and glycemic index for weight-loss maintenance.
    N Engl J Med. 2010 Nov 25;363(22):2102-13 PMID: 21105792
  135. Influence of apple polyphenols on inflammatory gene expression.
    Mol Nutr Food Res. 2009 Oct;53(10):1263-80 PMID: 19764067
  136. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome.
    BMC Gastroenterol. 2009;9:15 PMID: 19220890
  137. T-Independent immune response: new aspects of B cell biology.
    Science. 2000 Oct 6;290(5489):89-92 PMID: 11021805
  138. Lactobacillus rhamnosus GG culture supernatant ameliorates acute alcohol-induced intestinal permeability and liver injury.
    Am J Physiol Gastrointest Liver Physiol. 2012 Jul;303(1):G32-41 PMID: 22538402
  139. Acute alcohol-induced liver injury.
    Front Physiol. 2012 Jun 12;3:193 PMID: 22701432
  140. Prospective assessment of the predictive value of alpha-glutathione S-transferase for intestinal ischemia.
    Am Surg. 2003 Apr;69(4):324-9; discussion 329 PMID: 12716091
  141. Vitamin A deficiency exacerbates methotrexate-induced jejunal injury in rats.
    J Nutr. 1997 May;127(5):770-6 PMID: 9165000
  142. Endogenous cannabinoid system regulates intestinal barrier function in vivo through cannabinoid type 1 receptor activation.
    Am J Physiol Gastrointest Liver Physiol. 2012 Mar 1;302(5):G565-71 PMID: 22135307
  143. Limulus amebocyte lysate assay for detection of endotoxin in patients with sepsis syndrome. AMCC Sepsis Project Working Group.
    Clin Infect Dis. 1998 Sep;27(3):582-91 PMID: 9770160
  144. Effect of enteral nutrition and synbiotics on bacterial infection rates after pylorus-preserving pancreatoduodenectomy: a randomized, double-blind trial.
    Ann Surg. 2007 Jul;246(1):36-41 PMID: 17592288
  145. Synbiotic control of inflammation and infection in severe acute pancreatitis: a prospective, randomized, double blind study.
    Hepatogastroenterology. 2007 Mar;54(74):590-4 PMID: 17523328
  146. Probiotics in the intensive care unit.
    Curr Opin Crit Care. 2009 Apr;15(2):144-8 PMID: 19300087
  147. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome.
    Gut. 2010 Sep;59(9):1213-21 PMID: 20650926
  148. Salmonella enterica serovar Typhimurium effectors SopB, SopE, SopE2 and SipA disrupt tight junction structure and function.
    Cell Microbiol. 2006 Dec;8(12):1946-57 PMID: 16869830
  149. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.
    Lancet. 1999 Aug 21;354(9179):635-9 PMID: 10466665
  150. Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells.
    Am J Gastroenterol. 2012 Jan;107(1):75-81 PMID: 21931380
  151. Functional interactions between the gut microbiota and host metabolism.
    Nature. 2012 Sep 13;489(7415):242-9 PMID: 22972297
  152. Technology insight: calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease.
    Nat Clin Pract Gastroenterol Hepatol. 2005 Feb;2(2):96-102 PMID: 16265127
  153. Detection of chemotherapy-induced enterocyte toxicity with circulating intestinal fatty acid binding protein.
    J Pediatr Hematol Oncol. 2006 Apr;28(4):267-9 PMID: 16679929
  154. Calprotectin, a faecal marker of organic gastrointestinal abnormality.
    Lancet. 2000 Nov 25;356(9244):1783-4 PMID: 11117904
  155. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution.
    Gastroenterology. 2005 Aug;129(2):550-64 PMID: 16083712
  156. Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease.
    Gut. 2012 Aug;61(8):1146-53 PMID: 22115910
  157. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice.
    Hepatology. 2009 Oct;50(4):1094-104 PMID: 19637282
  158. Probiotic and postbiotic activity in health and disease: comparison on a novel polarised ex-vivo organ culture model.
    Gut. 2012 Jul;61(7):1007-15 PMID: 22301383
  159. The antibacterial lectin RegIIIgamma promotes the spatial segregation of microbiota and host in the intestine.
    Science. 2011 Oct 14;334(6053):255-8 PMID: 21998396
  160. Noninvasive measurement of intestinal epithelial damage at time of refeeding can predict clinical outcome after necrotizing enterocolitis.
    Pediatr Res. 2013 Feb;73(2):209-13 PMID: 23154757
  161. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial.
    Lancet. 2008 Feb 23;371(9613):651-9 PMID: 18279948
  162. The immune geography of IgA induction and function.
    Mucosal Immunol. 2008 Jan;1(1):11-22 PMID: 19079156
  163. Pathobionts of the gastrointestinal microbiota and inflammatory disease.
    Curr Opin Immunol. 2011 Aug;23(4):473-80 PMID: 21856139
  164. A guide to Ussing chamber studies of mouse intestine.
    Am J Physiol Gastrointest Liver Physiol. 2009 Jun;296(6):G1151-66 PMID: 19342508
  165. Kiwifruit extracts inhibit cytokine production by lipopolysaccharide-activated macrophages, and intestinal epithelial cells isolated from IL10 gene deficient mice.
    Cell Immunol. 2011;270(1):70-9 PMID: 21600571
  166. Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress.
    Gut. 2006 Nov;55(11):1553-60 PMID: 16638791
  167. Health benefits and health claims of probiotics: bridging science and marketing.
    Br J Nutr. 2011 Nov;106(9):1291-6 PMID: 21861940
  168. Lactobacilli facilitate maintenance of intestinal membrane integrity during Shigella dysenteriae 1 infection in rats.
    Nutrition. 2009 Mar;25(3):350-8 PMID: 19036564
  169. Diversity of the human intestinal microbial flora.
    Science. 2005 Jun 10;308(5728):1635-8 PMID: 15831718
  170. Microbial ecology: human gut microbes associated with obesity.
    Nature. 2006 Dec 21;444(7122):1022-3 PMID: 17183309
  171. Pilot study: alterations of intestinal microbiota in obese humans are not associated with colonic inflammation or disturbances of barrier function.
    Aliment Pharmacol Ther. 2010 Dec;32(11-12):1307-14 PMID: 21050232
  172. Intestinal permeability in patients with adverse reactions to food.
    Dig Liver Dis. 2006 Oct;38(10):732-6 PMID: 16880015
  173. Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics.
    J Physiol. 2012 Mar 1;590(Pt 5):1035-44 PMID: 22219336
  174. The intestinal microbiota and chronic disorders of the gut.
    Nat Rev Gastroenterol Hepatol. 2011 Sep;8(9):523-31 PMID: 21844910
  175. Identification of epithelial gaps in human small and large intestine by confocal endomicroscopy.
    Gastroenterology. 2007 Dec;133(6):1769-78 PMID: 18054549
  176. Effects of vitamin A supplementation on intestinal barrier function, growth, total parasitic, and specific Giardia spp infections in Brazilian children: a prospective randomized, double-blind, placebo-controlled trial.
    J Pediatr Gastroenterol Nutr. 2010 Mar;50(3):309-15 PMID: 20038852
  177. Epithelial crosstalk at the microbiota-mucosal interface.
    Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4607-14 PMID: 20826446
  178. Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews.
    Curr Opin Clin Nutr Metab Care. 2011 Nov;14(6):581-7 PMID: 21892075
  179. Non-invasive assessment of barrier integrity and function of the human gut.
    World J Gastrointest Surg. 2010 Mar 27;2(3):61-9 PMID: 21160852
  180. Relation of C-reactive protein to abdominal adiposity.
    Am J Cardiol. 2010 Jul 1;106(1):56-61 PMID: 20609648
  181. Host-bacterial mutualism in the human intestine.
    Science. 2005 Mar 25;307(5717):1915-20 PMID: 15790844
  182. Prebiotic approach alleviates hepatic steatosis: implication of fatty acid oxidative and cholesterol synthesis pathways.
    Mol Nutr Food Res. 2013 Feb;57(2):347-59 PMID: 23203768
  183. Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability.
    Br J Pharmacol. 2012 Apr;165(8):2598-610 PMID: 21745190
  184. Intestinal permeability in the critically ill.
    Intensive Care Med. 1992;18(1):38-41 PMID: 1578045
  185. A marketed fermented dairy product containing Bifidobacterium lactis CNCM I-2494 suppresses gut hypersensitivity and colonic barrier disruption induced by acute stress in rats.
    Neurogastroenterol Motil. 2012 Apr;24(4):376-e172 PMID: 22272920
  186. PASSCLAIM--gut health and immunity.
    Eur J Nutr. 2004 Jun;43 Suppl 2:II118-II173 PMID: 15221356
  187. Physiology and pathophysiology of splanchnic hypoperfusion and intestinal injury during exercise: strategies for evaluation and prevention.
    Am J Physiol Gastrointest Liver Physiol. 2012 Jul 15;303(2):G155-68 PMID: 22517770
  188. The bacterial virulence factor NleA is required for the disruption of intestinal tight junctions by enteropathogenic Escherichia coli.
    Cell Microbiol. 2010 Jan;12(1):31-41 PMID: 19712078
  189. Lactobacillus plantarum DSM 2648 is a potential probiotic that enhances intestinal barrier function.
    FEMS Microbiol Lett. 2010 Aug 1;309(2):184-92 PMID: 20618863
  190. Potentiation of polarized intestinal Caco-2 cell responsiveness to probiotics complexed with secretory IgA.
    J Biol Chem. 2010 Oct 29;285(44):33906-13 PMID: 20729211
  191. The immune system in irritable bowel syndrome.
    J Neurogastroenterol Motil. 2011 Oct;17(4):349-59 PMID: 22148103
  192. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin.
    J Hepatol. 2008 Jun;48(6):983-92 PMID: 18395289
  193. Intestinal permeability in irritable bowel syndrome patients: effects of NSAIDs.
    Dig Dis Sci. 2010 Mar;55(3):716-23 PMID: 19255843
  194. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut.
    J Physiol. 2012 Feb 1;590(Pt 3):447-58 PMID: 22124143
  195. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier.
    Gut. 2013 Aug;62(8):1160-8 PMID: 22637702
  196. EspM inhibits pedestal formation by enterohaemorrhagic Escherichia coli and enteropathogenic E. coli and disrupts the architecture of a polarized epithelial monolayer.
    Cell Microbiol. 2010 Apr 1;12(4):489-505 PMID: 19912240
  197. Enhanced translocation of bacteria across metabolically stressed epithelia is reduced by butyrate.
    Inflamm Bowel Dis. 2010 Jul;16(7):1138-48 PMID: 20024905
  198. Helicobacter pylori CagA targets PAR1/MARK kinase to disrupt epithelial cell polarity.
    Nature. 2007 May 17;447(7142):330-3 PMID: 17507984
  199. The effect of intestinal hypoperfusion on intestinal absorption and permeability during cardiopulmonary bypass.
    Gastroenterology. 1994 Feb;106(2):318-23 PMID: 8299899
  200. Loss of claudins 2 and 15 from mice causes defects in paracellular Na+ flow and nutrient transport in gut and leads to death from malnutrition.
    Gastroenterology. 2013 Feb;144(2):369-80 PMID: 23089202
  201. The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases.
    Gastroenterology. 2011 May;140(6):1720-28 PMID: 21530738
  202. Role of serotonin in intestinal inflammation: knockout of serotonin reuptake transporter exacerbates 2,4,6-trinitrobenzene sulfonic acid colitis in mice.
    Am J Physiol Gastrointest Liver Physiol. 2009 Mar;296(3):G685-95 PMID: 19095763
  203. Of mice and not men: differences between mouse and human immunology.
    J Immunol. 2004 Mar 1;172(5):2731-8 PMID: 14978070
  204. Metformin protects against the development of fructose-induced steatosis in mice: role of the intestinal barrier function.
    Lab Invest. 2012 Jul;92(7):1020-32 PMID: 22525431
  205. Increased intestinal macromolecular permeability and urine nitrite excretion associated with liver cirrhosis with ascites.
    World J Gastroenterol. 2008 Jun 28;14(24):3884-90 PMID: 18609714
  206. Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis.
    Aliment Pharmacol Ther. 2012 Feb;35(3):327-34 PMID: 22150569
  207. Identification of a bacterial type III effector family with G protein mimicry functions.
    Cell. 2006 Jan 13;124(1):133-45 PMID: 16413487
  208. Is small intestinal permeability really increased in relatives of patients with Crohn's disease?
    Gastroenterology. 1993 Jun;104(6):1627-32 PMID: 8500719
  209. Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon.
    Aliment Pharmacol Ther. 2010 Apr;31(8):874-82 PMID: 20102355
  210. Postabsorptive plasma citrulline concentration is a marker of absorptive enterocyte mass and intestinal failure in humans.
    Gastroenterology. 2000 Dec;119(6):1496-505 PMID: 11113071
  211. Rapid development of intestinal cell damage following severe trauma: a prospective observational cohort study.
    Crit Care. 2009;13(3):R86 PMID: 19505335
  212. Protective effect of galactooligosaccharide-supplemented enteral nutrition on intestinal barrier function in rats with severe acute pancreatitis.
    Clin Nutr. 2009 Oct;28(5):575-80 PMID: 19525042
  213. Helicobacter pylori dysregulation of gastric epithelial tight junctions by urease-mediated myosin II activation.
    Gastroenterology. 2009 Jan;136(1):236-46 PMID: 18996125
  214. Increased proteasome-mediated degradation of occludin in irritable bowel syndrome.
    Am J Gastroenterol. 2010 May;105(5):1181-8 PMID: 19997094
  215. Show me the pathway! Regulation of paracellular permeability by Na(+)-glucose cotransport.
    Adv Drug Deliv Rev. 2000 Jun 30;41(3):265-81 PMID: 10854686
  216. The gastrointestinal tract stem cell niche.
    Stem Cell Rev. 2006;2(3):203-12 PMID: 17625256
  217. Effect of probiotics on gastrointestinal symptoms and small intestinal permeability in children with atopic dermatitis.
    J Pediatr. 2004 Nov;145(5):612-6 PMID: 15520759
  218. Immune adaptations that maintain homeostasis with the intestinal microbiota.
    Nat Rev Immunol. 2010 Mar;10(3):159-69 PMID: 20182457
  219. Gut luminal lactate measured by microdialysis mirrors permeability of the intestinal mucosa after ischemia.
    Shock. 2008 Feb;29(2):245-51 PMID: 17693938
  220. Relationship of antibodies to endotoxin core to mortality in medical patients with sepsis syndrome.
    Intensive Care Med. 1999 May;25(5):435-44 PMID: 10401935
  221. Intestinal mucosal barrier function in health and disease.
    Nat Rev Immunol. 2009 Nov;9(11):799-809 PMID: 19855405
  222. Plasma concentrations of glutathione S-transferase isoenzyme are raised in patients with intestinal ischaemia.
    Br J Surg. 1999 Oct;86(10):1349-53 PMID: 10540149
  223. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome.
    Gastroenterology. 2007 Jan;132(1):26-37 PMID: 17241857
  224. Requirement of cellular prion protein for intestinal barrier function and mislocalization in patients with inflammatory bowel disease.
    Gastroenterology. 2012 Jul;143(1):122-32.e15 PMID: 22446194
  225. Non-alcoholic steatohepatitis: a non-invasive diagnosis by analysis of exhaled breath.
    J Hepatol. 2013 Mar;58(3):543-8 PMID: 23142062
  226. How host-bacterial interactions lead to IgA synthesis in the gut.
    Trends Immunol. 2008 Nov;29(11):523-31 PMID: 18838301
  227. Gastrointestinal permeability in celiac disease.
    Gastroenterology. 1997 Apr;112(4):1129-36 PMID: 9097995
  228. L. plantarum prevents enteroinvasive Escherichia coli-induced tight junction proteins changes in intestinal epithelial cells.
    BMC Microbiol. 2009;9:63 PMID: 19331693
  229. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche.
    Nature. 2009 May 14;459(7244):262-5 PMID: 19329995
  230. Endotoxin-neutralizing capacity of serum from cardiac surgical patients.
    J Cardiothorac Vasc Anesth. 2001 Aug;15(4):451-4 PMID: 11505348
  231. Fecal expression of human β-defensin-2 following birth.
    Neonatology. 2010;98(4):365-9 PMID: 20980773
  232. Additional value of serum I-FABP levels for evaluating celiac disease activity in children.
    Scand J Gastroenterol. 2011 Dec;46(12):1435-41 PMID: 22029621
  233. Food allergy and eosinophilic gastroenteritis and colitis.
    Curr Opin Allergy Clin Immunol. 2010 Jun;10(3):238-45 PMID: 20431371
  234. Probiotic bacteria induce maturation of intestinal claudin 3 expression and barrier function.
    Am J Pathol. 2012 Feb;180(2):626-35 PMID: 22155109
  235. Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis.
    Br J Surg. 2002 Sep;89(9):1103-7 PMID: 12190674
  236. Interleukin-1 receptor phosphorylation activates Rho kinase to disrupt human gastric tight junctional claudin-4 during Helicobacter pylori infection.
    Cell Microbiol. 2010 May 1;12(5):692-703 PMID: 20070312
  237. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment.
    EMBO Mol Med. 2011 Sep;3(9):559-72 PMID: 21735552
  238. Rapid lamina propria retraction and zipper-like constriction of the epithelium preserves the epithelial lining in human small intestine exposed to ischaemia-reperfusion.
    J Pathol. 2011 Jul;224(3):411-9 PMID: 21547908
  239. Visceral injury and systemic inflammation in patients undergoing extracorporeal circulation during aortic surgery.
    Ann Surg. 2008 Jul;248(1):117-25 PMID: 18580215
  240. Epithelial cell extrusion requires the sphingosine-1-phosphate receptor 2 pathway.
    J Cell Biol. 2011 May 16;193(4):667-76 PMID: 21555463
  241. Heterogeneous metabolic adaptation of C57BL/6J mice to high-fat diet.
    Am J Physiol Endocrinol Metab. 2002 Apr;282(4):E834-42 PMID: 11882503
  242. Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients.
    Transplantation. 2002 Jul 15;74(1):123-7 PMID: 12134110
  243. Dietary fiber intake and mortality in the NIH-AARP diet and health study.
    Arch Intern Med. 2011 Jun 27;171(12):1061-8 PMID: 21321288
  244. Increased gastric and intestinal permeability in patients with Crohn's disease.
    Am J Gastroenterol. 1997 Oct;92(10):1891-6 PMID: 9382060
  245. Lactobacillus casei downregulates commensals' inflammatory signals in Crohn's disease mucosa.
    Inflamm Bowel Dis. 2009 Feb;15(2):275-83 PMID: 18839424
  246. Increased intestinal permeability in malnourished patients with liver cirrhosis.
    Eur J Clin Nutr. 2012 Oct;66(10):1116-9 PMID: 22872031
  247. The endocannabinoid system links gut microbiota to adipogenesis.
    Mol Syst Biol. 2010 Jul;6:392 PMID: 20664638
  248. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis.
    Am J Gastroenterol. 2005 Jul;100(7):1539-46 PMID: 15984978
  249. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair.
    Cell Microbiol. 2007 Mar;9(3):804-16 PMID: 17087734
  250. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome.
    Am J Physiol Gastrointest Liver Physiol. 2012 Oct;303(7):G775-85 PMID: 22837345
  251. Crowding induces live cell extrusion to maintain homeostatic cell numbers in epithelia.
    Nature. 2012 Apr 26;484(7395):546-9 PMID: 22504183
  252. Reciprocal interactions of the intestinal microbiota and immune system.
    Nature. 2012 Sep 13;489(7415):231-41 PMID: 22972296
  253. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis.
    Am J Gastroenterol. 2009 Feb;104(2):437-43 PMID: 19174792
  254. A new model to study intestinal ischemia-reperfusion damage in man.
    J Surg Res. 2011 Apr;166(2):222-6 PMID: 20070978
  255. Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire.
    Blood. 2004 Dec 1;104(12):3647-54 PMID: 15191950
  256. Small bowel and colonic permeability to 51Cr-EDTA in patients with active inflammatory bowel disease.
    Clin Invest Med. 1988 Apr;11(2):151-5 PMID: 3135136
  257. Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies.
    Aliment Pharmacol Ther. 2013 Feb;37(4):482-90 PMID: 23289539
  258. New Insight in Loss of Gut Barrier during Major Non-Abdominal Surgery.
    PLoS One. 2008;3(12):e3954 PMID: 19088854
  259. Interplay between obesity and associated metabolic disorders: new insights into the gut microbiota.
    Curr Opin Pharmacol. 2009 Dec;9(6):737-43 PMID: 19628432
  260. Non-invasive markers for early diagnosis and determination of the severity of necrotizing enterocolitis.
    Ann Surg. 2010 Jun;251(6):1174-80 PMID: 20485148
  261. Novel multi-sugar assay for site-specific gastrointestinal permeability analysis: a randomized controlled crossover trial.
    Clin Nutr. 2013 Apr;32(2):245-51 PMID: 22892368
  262. Purified galactooligosaccharide, derived from a mixture produced by the enzymic activity of Bifidobacterium bifidum, reduces Salmonella enterica serovar Typhimurium adhesion and invasion in vitro and in vivo.
    J Med Microbiol. 2010 Dec;59(Pt 12):1428-39 PMID: 20798214
  263. The role of diet in symptoms of irritable bowel syndrome in adults: a narrative review.
    J Am Diet Assoc. 2009 Jul;109(7):1204-14 PMID: 19559137
  264. Distinct effects of Vibrio cholerae haemagglutinin/protease on the structure and localization of the tight junction-associated proteins occludin and ZO-1.
    Cell Microbiol. 2000 Feb;2(1):11-7 PMID: 11207559
  265. Identification of specific miRNAs targeting proteins of the apical junctional complex that simulate the probiotic effect of E. coli Nissle 1917 on T84 epithelial cells.
    Int J Biochem Cell Biol. 2012 Feb;44(2):341-9 PMID: 22101077
Article Info
Journal
BMC gastroenterology
Abbr.
BMC Gastroenterol
ISSN
1471-230X
Published
2014-11-18
Epub
2014-00-18
Pages
189
Language
English
Region
England
NLM ID
100968547
PMCID
PMC4253991
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com